Aims: Metyrapone causes a decrease in the serum cortisol level without affecting ACTH production in ectopic tumors. We report a case who presented with Cushing’s syndrome due to an ectopic ACTH-producing thymic carcinoid. In the present case, it was demonstrated that metyrapone administration resulted in a significant decrease in the plasma ACTH and serum cortisol levels. We hypothesized that the steroid hormone may promote proopiomelanocortin (POMC) gene expression in the carcinoid cells. Methods: An 11-year-old boy presented with Cushing’s syndrome. Prior to the detection of a thymic tumor, metyrapone was administered to ameliorate the symptoms of Cushing’s syndrome. Interestingly, plasma ACTH as well as serum cortisol levels immediately decreased after metyrapone administration. The levels of cortisol and ACTH were observed to be normal after complete surgical resection of the tumor. Biological characterization of the tumor cells was by in vitro analysis. Results: Thein vitro culture of the tumor cells showed an increased expression of POMC in the presence of cortisol. A CpG methylation assay showed that the demethylation of the POMC promoter was induced by a steroid hormone. Conclusion: These findings suggest that the ectopic ACTH-producing tumor may partly be regulated by the elevated levels of cortisol.

Keywords:
ACTH, Cortisol, Gene expression, Proopiomelanocortin, Steroid
1.
Beuschlein F, Hammer GD: Ectopic pro-opiomelanocortin syndrome. Endocrinol Metab Clin North Am 2002;31:191–234.
2.
Gartner LN, Voorhess ML: Adrenocorticotropic hormone-producing thymic carcinoid in a teenager. Cancer 1993;71:106–111.
3.
Rosai J, Higa E: Mediastinal endocrine neoplasm, of probable thymic origin, related to carcinoid tumor. Clinicopathologic study of 8 cases. Cancer 1972;29:1061–1074.
4.
Detterbeck FC, Parsons AM: Thymic tumors. Ann Thorac Surg 2004;77:1860–1869.
5.
Ye L, Li X, Kong X, Wang W, Bi Y, Hu L, Cui B, Li X, Ning G: Hypomethylation in the promoter region of POMC gene correlates with ectopic overexpression in thymic carcinoids. J Endocrinol 2005;185:337–343.
6.
White A, Ray DW, Talbot A, Abraham P, Thody AJ, Bevan JS: Cushing’s syndrome due to pheochromocytoma secreting the precursors of adrenocorticotropin. J Clin Endocrinol Metab 2000;85:4771–4775.
7.
Beardwell CG, Adamson AR, Shalet SM: Prolonged remission in florid Cushing’s syndrome following metyrapone treatment. Clin Endocrinol 1981;14:485–492.
8.
Liu J, Heikkila P, Voutilainen R, Karonen SL, Kahri AI: Pheochromocytoma expressing adrenocorticotropin and corticotropin-releasing hormone; regulation by glucocorticoids and nerve growth factor. Eur J Endocrinol 1994;131:221–228.
9.
Thomassin H, Flavin M, Espinas ML, Grange T: Glucocorticoid-induced DNA demethylation and gene memory during development. EMBO J 2001;20:1974–1983.
10.
Lamonerie T, Tremblay JJ, Lanctot C, Therrien M, Gauthier Y, Drouin J: Ptx1, a bicoid-related homeo box transcription factor involved in transcription of the pro-opiomelanocortin gene. Genes Dev 1996;10:1284–1295.
11.
Maira M, Martens C, Philips A, Drouin J: Heterodimerization between members of the Nur subfamily of orphan nuclear receptors as a novel mechanism for gene activation. Mol Cell Biol 1999;19:7549–7557.
12.
Lamolet B, Pulichino AM, Lamonerie T, Gauthier Y, Brue T, Enjalbert A, Drouin J: A pituitary cell-restricted T box factor, Tpit, activates POMC transcription in cooperation with Pitx homeoproteins. Cell 2001;104:849–859.
13.
Picon A, Bertagna X, de Keyzer Y: Analysis of the human proopiomelanocortin gene promoter in a small cell lung carcinoma cell line reveals an unusual role for E2F transcription factors. Oncogene 1999;18:2627–2633.
© 2007 S. Karger AG, Basel
2007
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.